Evidence map›Paper›PMID 40704837›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Microphysiological Solid Tumor Models in Hydrogel Beads for CAR T Cell Immunotherapy Evaluation.

Xuan Peng, Željko Janićijević, Liliana R Loureiro, Lydia Hoffmann, Poh Soo Lee, Isli Cela, Benjamin Kruppke, Alexandra Kegler, Anja Feldmann, Ielizaveta Gorodetska and 5 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Xuan PengHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328, Dresden, Germany.
Željko JanićijevićHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328, Dresden, Germany.
Liliana R LoureiroHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328, Dresden, Germany.
Lydia HoffmannHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328, Dresden, Germany.
Poh Soo LeeMax Bergmann Center of Biomaterials and Institute of Materials Science, Technische Universität Dresden, 01069, Dresden, Germany.
Isli CelaHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328, Dresden, Germany.
Benjamin KruppkeMax Bergmann Center of Biomaterials and Institute of Materials Science, Technische Universität Dresden, 01069, Dresden, Germany.
Alexandra KeglerHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328, Dresden, Germany.
Anja FeldmannHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328, Dresden, Germany.
Ielizaveta GorodetskaFaculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307, Dresden, Germany.
Anja Madleine MarklHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328, Dresden, Germany.
Anna DubrovskaFaculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307, Dresden, Germany.
Anne Kathrin OffermannGerhard Domagk Institute of Pathology, University Hospital Münster, 48149, Münster, Germany.
Michael BachmannHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328, Dresden, Germany.
Larysa BarabanHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328, Dresden, Germany.ORCID https://orcid.org/0000-0003-1010-2791

Funding

China Scholarship Council 202006630001Horizon Europe European Research Council (ERC) 101045415
6 · The paper itself

Abstract

Micrometastases are challenging to resect surgically and to detect with in vivo imaging. Immunotherapy is highly anticipated to revolutionize their treatment, but its overall efficacy still remains limited for solid tumors. Here, a 3D micrometastases model is developed to mimic key microenvironmental cues, enabling in vitro evaluation of chimeric antigen receptor (CAR) T cell immunotherapy. Prostate cancer that preferentially metastasizes to, e.g., liver or bone marrow, is utilized as a model. Hydrogel beads with an elastic modulus matching those of soft organs are used to support long-term culturing, immunostaining, and monitoring of the spheroids. As a biochemical cue, the impact of fibroblast activation protein (FAP), an emerging target in the tumor microenvironment, is investigated on prostate cancer spheroids and on the efficacy of CAR T cell therapy. The multi-spheroid model consists of prostate stem cell antigen (PSCA)-expressing prostate cancer cells and FAP-producing fibrosarcoma cells in varying ratios. The morphological features of the model are compared to clinical histopathology and metastatic murine model samples. Finally, CAR T cell trials demonstrate successful chemoattraction and infiltration through the hydrogel matrix, with a dual-targeting approach against FAP and PSCA antigens showing synergistic efficacy. This research provides invaluable insights for engineering 3D tumor models and modeling therapies targeting small metastatic or residual tumors, suggesting that co-targeting may be a more effective strategy to unlock the tumor microenvironment's suppression.

Indexed as

HydrogelsImmunotherapy, AdoptiveProstatic NeoplasmsReceptors, Chimeric AntigenAnimalsCell Line, TumorHumansMaleMiceSpheroids, CellularTumor MicroenvironmentHydrogelsReceptors, Chimeric Antigendroplet microfluidicsfibroblast activation proteinimmunotherapymicrometastasesPEGDA hydrogel beadstumor microenvironment

Identifiers

PMID40704837
PMCPMC12591166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.